Pharmacological reversal of synaptic and network pathology in human MECP2‐KO neurons and cortical organoids

Duplication or deficiency of the X‐linked MECP2 gene reliably produces profound neurodevelopmental impairment. MECP2 mutations are almost universally responsible for Rett syndrome (RTT), and particular mutations and cellular mosaicism of MECP2 may underlie the spectrum of RTT symptomatic severity. No clinically approved treatments for RTT are currently available, but human pluripotent stem cell technology offers a platform to identify neuropathology and test candidate therapeutics. Using a strategic series of increasingly complex human stem cell‐derived technologies, including human neurons, MECP2‐mosaic neurospheres to model RTT female brain mosaicism, and cortical organoids, we identified synaptic dysregulation downstream from knockout of MECP2 and screened select pharmacological compounds for their ability to treat this dysfunction. Two lead compounds, Nefiracetam and PHA 543613, specifically reversed MECP2‐knockout cytologic neuropathology. The capacity of these compounds to reverse neuropathologic phenotypes and networks in human models supports clinical studies for neurodevelopmental disorders in which MeCP2 deficiency is the predominant etiology.

[1]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[2]  Eric C. Griffith,et al.  Characterization of human mosaic Rett syndrome brain tissue by single-nucleus RNA sequencing , 2018, Nature Neuroscience.

[3]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[4]  Madeline A. Lancaster,et al.  Human cerebral organoids recapitulate gene expression programs of fetal neocortex development , 2015, Proceedings of the National Academy of Sciences.

[5]  Thomas Miconi,et al.  Biologically plausible learning in recurrent neural networks reproduces neural dynamics observed during cognitive tasks , 2016, bioRxiv.

[6]  Stephen D. Shea,et al.  MECP2 regulates cortical plasticity underlying a learned behaviour in adult female mice , 2016, Nature Communications.

[7]  S. Moriguchi Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II. , 2011, Journal of pharmacological sciences.

[8]  F. Hanefeld,et al.  An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. , 2002, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[9]  S. Pati,et al.  Rett Syndrome: Reaching for Clinical Trials , 2015, Neurotherapeutics.

[10]  R. Kooy,et al.  The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders , 2015, Neuron.

[11]  M. Zaks,et al.  Synaptic noise induces intermittent oscillatory-quiescent state transitions in a spiking network model , 2017, 1709.09748.

[12]  Thomas J. Raub,et al.  Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. , 2006, Journal of medicinal chemistry.

[13]  Huanming Yang,et al.  An atlas of the protein-coding genes in the human, pig, and mouse brain , 2020, Science.

[14]  G. Mandel,et al.  MeCP2 Is Critical for Maintaining Mature Neuronal Networks and Global Brain Anatomy during Late Stages of Postnatal Brain Development and in the Mature Adult Brain , 2012, The Journal of Neuroscience.

[15]  A. Bird,et al.  Rett Syndrome: Crossing the Threshold to Clinical Translation , 2016, Trends in Neurosciences.

[16]  Peter J. Park,et al.  Somatic mutation in single human neurons tracks developmental and transcriptional history , 2015, Science.

[17]  David A. Orlando,et al.  Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. , 2013, Cell stem cell.

[18]  A. L. Camp,et al.  Swimming muscles power suction feeding in largemouth bass , 2015, Proceedings of the National Academy of Sciences.

[19]  D. Buonomano,et al.  Complexity without chaos: Plasticity within random recurrent networks generates robust timing and motor control , 2012, 1210.2104.

[20]  Yen-Chu Lin,et al.  Defective GABAergic neurotransmission in the nucleus tractus solitarius in Mecp2-null mice, a model of Rett syndrome , 2018, Neurobiology of Disease.

[21]  Max F. Oginsky,et al.  Alterations in the cholinergic system of brain stem neurons in a mouse model of Rett syndrome. , 2014, American journal of physiology. Cell physiology.

[22]  Terrence J. Sejnowski,et al.  Simple framework for constructing functional spiking recurrent neural networks , 2019, Proceedings of the National Academy of Sciences.

[23]  M. Pike,et al.  Somatic Mutation , 1965, British medical journal.

[24]  M. Higley,et al.  Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior , 2012, Neuron.

[25]  K. Delaney,et al.  MeCP2 Mutation Results in Compartment-Specific Reductions in Dendritic Branching and Spine Density in Layer 5 Motor Cortical Neurons of YFP-H Mice , 2012, PloS one.

[26]  A. Yaroshinsky,et al.  A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. , 2017, Pediatric neurology.

[27]  Eric C. Griffith,et al.  Brain-Specific Phosphorylation of MeCP2 Regulates Activity-Dependent Bdnf Transcription, Dendritic Growth, and Spine Maturation , 2006, Neuron.

[28]  J. Lupski,et al.  Altered neuronal network and rescue in a human MECP2 duplication model , 2015, Molecular Psychiatry.

[29]  S. Moshé,et al.  Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate. , 2016, Pediatric neurology.

[30]  Stephen T. C. Wong,et al.  MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription , 2008, Science.

[31]  Gene W. Yeo,et al.  Complex Oscillatory Waves Emerging from Cortical Organoids Model Early Human Brain Network Development. , 2019, Cell stem cell.

[32]  Christian Rosenmund,et al.  MeCP2 Controls Excitatory Synaptic Strength by Regulating Glutamatergic Synapse Number , 2007, Neuron.

[33]  A. Muotri,et al.  Brain Organoids as Tools for Modeling Human Neurodevelopmental Disorders. , 2019, Physiology.

[34]  Daniele Linaro,et al.  Pyramidal Neurons Derived from Human Pluripotent Stem Cells Integrate Efficiently into Mouse Brain Circuits In Vivo , 2013, Neuron.

[35]  Fred H. Gage,et al.  A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells , 2010, Cell.

[36]  S. Duan,et al.  Loss of MeCP2 in cholinergic neurons causes part of RTT-like phenotypes via α7 receptor in hippocampus , 2016, Cell Research.

[37]  M. Johnston,et al.  Neurobiology of Rett Syndrome , 2003, Journal of child neurology.

[38]  Rodney C Samaco,et al.  Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. , 2005, Human molecular genetics.

[39]  M. Sur,et al.  Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice , 2019, Science Translational Medicine.

[40]  Ryan E. Mills,et al.  Intersection of diverse neuronal genomes and neuropsychiatric disease: The Brain Somatic Mosaicism Network , 2017, Science.

[41]  Jim Selfridge,et al.  The role of MeCP2 in the brain. , 2009, Annual review of cell and developmental biology.

[42]  H. Zoghbi,et al.  Learning and Memory and Synaptic Plasticity Are Impaired in a Mouse Model of Rett Syndrome , 2006, The Journal of Neuroscience.

[43]  S. Nelson,et al.  Intact Long-Term Potentiation but Reduced Connectivity between Neocortical Layer 5 Pyramidal Neurons in a Mouse Model of Rett Syndrome , 2009, The Journal of Neuroscience.

[44]  D. Benke,et al.  Impact on GABA systems in monogenetic developmental CNS disorders: Clues to symptomatic treatment , 2017, Neuropharmacology.

[45]  Heather M. O'Leary,et al.  Placebo‐controlled crossover assessment of mecasermin for the treatment of Rett syndrome , 2018, Annals of clinical and translational neurology.

[46]  Allan R. Jones,et al.  Conserved cell types with divergent features in human versus mouse cortex , 2019, Nature.

[47]  Eric C. Griffith,et al.  Derepression of BDNF Transcription Involves Calcium-Dependent Phosphorylation of MeCP2 , 2003, Science.

[48]  A. Malykh,et al.  Piracetam and Piracetam-Like Drugs , 2010, Drugs.

[49]  Bing Zhang,et al.  WebGestalt: an integrated system for exploring gene sets in various biological contexts , 2005, Nucleic Acids Res..

[50]  E. Kirkness,et al.  Somatic coding mutations in human induced pluripotent stem cells , 2011, Nature.

[51]  H. Hakusui,et al.  Pharmacokinetics of nefiracetam and three metabolites in humans and stereoselective hydroxylation of its pyrrolidine ring. , 1993, Xenobiotica; the fate of foreign compounds in biological systems.

[52]  Joseph R Ecker,et al.  Cerebral Organoids Recapitulate Epigenomic Signatures of the Human Fetal Brain. , 2016, Cell reports.

[53]  Meghan T. Miller,et al.  Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder , 2019, Brain : a journal of neurology.

[54]  H. Sompolinsky,et al.  Chaos in Neuronal Networks with Balanced Excitatory and Inhibitory Activity , 1996, Science.

[55]  Heather M. O'Leary,et al.  Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome , 2014, Proceedings of the National Academy of Sciences.

[56]  Michael L. Gonzales,et al.  The Role of MeCP2 in Brain Development and Neurodevelopmental Disorders , 2010, Current psychiatry reports.

[57]  A. Muotri,et al.  Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation. , 2017, Cell stem cell.

[58]  Wei Wu,et al.  Selective preservation of cholinergic MeCP2 rescues specific Rett-syndrome-like phenotypes in MeCP2stop mice , 2017, Behavioural Brain Research.

[59]  C. Tronel,et al.  Alpha-7 nicotinic acetylcholine receptor agonist treatment in a rat model of Huntington's disease and involvement of heme oxygenase-1 , 2018, Neural regeneration research.

[60]  Ryan Gordon,et al.  Functional and Mechanistic Neurotoxicity Profiling Using Human iPSC-Derived Neural 3D Cultures , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[61]  N. Craddock,et al.  MECP2 structural and 3′‐UTR variants in schizophrenia, autism and other psychiatric diseases: A possible association with autism , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[62]  J. Clayton-Smith,et al.  Angelman syndrome phenotype associated with mutations inMECP2, a gene encoding a methyl CpG binding protein , 2001, Journal of medical genetics.

[63]  R. Robinson,et al.  Double-blind treatment of apathy in patients with poststroke depression using nefiracetam. , 2009, The Journal of neuropsychiatry and clinical neurosciences.

[64]  Anders M. Dale,et al.  A human neurodevelopmental model for Williams syndrome , 2016, Nature.

[65]  Rodney C. Samaco,et al.  GABAergic dysfunction mediates autism-like stereotypies and Rett syndrome phenotypes , 2010, Nature.